March 29th, 2013 An SOD1-related familial ALS trial under the direction of NEALS researchers Timothy Miller, MD, PhD (Washington University School of Medicine) and Merit Cudkowicz (Massachusetts General Hospital) indicates that antisense oligonucleotide delivery to the central nervous system may be a feasible therapeutic strategy in treating ALS.
James D. Berry, MD, MPH, (Massachusetts General Hospital & Harvard Medical School) has received the Richard Olney, MD, Clinician-Scientist Development Award for his investigation of cells in the immune system.
Led by Robert Brown, DPhil, MD (University of Massachusetts) and Jeffery Rothstein, MD, PhD (Johns Hopkins), the SAB met in Boston, MA this past February.
NEALS welcomes Dr. Robert Bowser (Barrow Neurological Institute) and Dr. Tim Miller (Washington University, St. Louis) to the Executive Committee!
A study led by St. Jude Children's Research Hospital has discovered mutations in two genes that lead to the death of nerve cells in ALS and related degenerative diseases.
We have had many inquires regarding the Brainstorm Stem Cell Therapeutics Clinical Trial. Read the US Brainstorm Trial.
PALS, caregivers, scientists, and ALS advocates gave their testimonies to a panel of FDA representatives at the first-ever ALS-specific FDA hearing. Speakers pushed for a partnership to get ALS treatments to PALS as fast as possible. Read the ALS Association.
PALS, caregivers, ALS advocates and researchers will gather on Monday February 25th to talk to the FDA about ALS, from the patient perspective.
Biogen Idec announced phase III EMPOWER trial did not reach its endpoints and did not show efficacy. NEALS Co-Chair Merit Cudkowicz reacts, "While we had all hoped for a positive result, ALS researchers remain truly committed to finding a cure for this disease."
